Long-Term Efficacy of High-Dose Imatinib in Hispanic Patients Without Access to Second-Generation Tyrosine Kinase Inhibitors Treated in LATAM Centers. - Cantu-Rodriguez OG; Osorno-Rodriguez KL; Dorsey-Trevino EG; Gutierrez-Aguirre CH; Jaime-Perez JC; Gomez-Villarreal JP; Rios-Rodelo MR; Gonzalez-Cantu GA; Contreras-Arce A; Colunga-Pedraza PR; Gomez-De Leon A; Mancias-Guerra MDC; et al. (Clinical lymphoma, myeloma & leukemia, 2023)